Low quality sentence examples
U zdravih davatelja koji su primali G-CSF uočene su prolazne citogenetske abnormalnosti.
Transient cytogenetic abnormalities have been observed in normal donors following G-CSF use.Liječenje se ne smije započinjati u bolesnika s postojećim citogenetskim abnormalnostima na kromosomu 7.
The treatment should not be initiated when the patients have existing cytogenetic abnormalities of chromosome 7.Citogenetske abnormalnosti i progresija u MDS/AML u bolesnika s teškom aplastičnom anemijom.
Cytogenetic abnormalities and progression to MDS/AML in patients with SAA.SLAMF7 se u velikoj mjeri eksprimira na stanicama multiplog mijeloma neovisno o citogenetskim abnormalnostima.
SLAMF7 is highly expressed on multiple myeloma cells independent of cytogenetic abnormalities.Učinkovitost Gliveca temelji se na općim hematološkim i citogenetskim stopama odgovora
The effectiveness of Glivec is based on overall haematological and cytogenetic response ratesBolesnika otkrile su da su svi ti bolesnici ostali u citogenetskoj remisiji raspon 32-38 mjeseci.
Patients revealed that all these patients remained in cytogenetic remission range 32-38 months.Primarna mjera ishoda bila je udio potvrđenog potpunog citogenetskog odgovora(cCCyR) unutar 12 mjeseci.
The primary endpoint was the rate of confirmed complete cytogenetic response(cCCyR) within 12 months.Nije poznato povećava li eltrombopag rizik od citogenetskih abnormalnosti u bolesnika s teškom aplastičnom anemijom.
It is not known whether eltrombopag increases the risk of cytogenetic abnormalities in patients with SAA.Ovaj citogenetski rezultat će u principu biti završen tek nakon 14 dana.
This Anant thread is removed after 14 days.Primarni ishod bio je značajni citogenetski odgovor(MCyR) u 12. tjednu liječenja.
The primary endpoint was MCyR at 12 weeks.Glavni sekundarni ishodi bili su značajan citogenetski odgovor prema ukupnoj razini dnevne doze u bolesnika otpornih na imatinib.
The main secondary endpoint was MCyR by total daily dose level in the imatinib-resistant patients.Značajni citogenetski odgovor postigao se u 55% bolesnika otpornih na imatinib i 82% bolesnika koji nisu podnosili imatinib.
MCyR was achieved in 55% of imatinib-resistant patients and 82% of imatinib-intolerant patients.U ispitivanju KML u kroničnoj fazi, za primarni ishod ispitivanja odabran je značajan citogenetski odgovor u bolesnika otpornih na imatinib.
In the study in chronic phase CML, the primary endpoint was MCyR in imatinib-resistant patients.Filgrastim se ne smije davati bolesnicima s teškom kongenitalnom neutropenijom(Kostmanov sindrom) u kojih citogenetski nalaz nije uredan vidjeti niže.
Filgrastim should not be administered to patients with severe congenital neutropenia(Kostman's syndrome) with abnormal cytogenetics see below.Na temelju procjene po Kaplan-Meieru, značajan citogenetski odgovor održao se tijekom 18 mjeseci u 93% 95% CI: 88%-98.
Based on the Kaplan-Meier estimates, the proportion of patients treated with dasatinib 100 mg once daily who maintained MCyR for 18 months was 93% 95% CI: 88%-98.Intolerancija na imatinib obuhvaćala je bolesnike koji su prestali uzimati imatinib zbog toksičnosti te koji nisu postigli veliki citogenetski odgovor u vrijeme ulaska u ispitivanje.
Imatinib intolerance included patients who discontinued imatinib because of toxicity and were not in major cytogenetic response at time of study entry.U ovom je ispitivanju kod 65% bolesnika postignut veliki citogenetski odgovor koji je bio potpun u 53%(potvrđeno 43%) bolesnika Tablica 3.
In this study 65% of the patients achieved a major cytogenetic response that was complete in 53%(confirmed 43%) of patients Table 3.U toj populaciji bolesnika koji su primali dasatinib u dozi od 100 mg jedanput dnevno, značajan citogenetski odgovor postigao se u 77% i potpun citogenetski odgovor u 67.
In this population of patients who received 100 mg once daily, MCyR was achieved in 77% and CCyR in 67.Odrediti stupanj asocijacije konstitucijskih osobitosti kariotipa i maligne transformacije, a u želji da se definiraju citogenetski faktori koji povećavaju rizik malignih bolesti u djece.
The aim of the study was to determine the degree of association of cytogenetically evident changes of constitutional karyotype and malignant process in children.Osobito treba istaknuti da je potpuni citogenetski odgovor zabilježen u 22% bolesnika u skupini na dasatinibu te u samo 8% bolesnika u skupini na imatinibu.
Notably, 22% of patients reported a complete cytogenetic response(CCyR) in the dasatinib arm while only 8% achieved a CCyR in the imatinib arm.
